Status:
COMPLETED
Spanish Real-World Evidence Cabozantinib
Lead Sponsor:
Spanish Oncology Genito-Urinary Group
Collaborating Sponsors:
Syntax for Science, S.L
Ipsen
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
RCC (Renal Cell Carcinoma) is the most common form of kidney cancer, accounting for 2-3% of all adult malignancies and for 90% of all kidney cancers. The incidence of RCC has steadily increased over t...
Eligibility Criteria
Inclusion
- Male or females, aged 18 years or older.
- Diagnosis of advanced Renal Cell Carcinoma (RCC)
- Alive or dead patients at study initiation who received at least one dose of cabozantinib for the treatment of RCC between October 2016 and 1 st June 2019.
- Alive patients who agree to participate and signed the Informed Consent Form (ICF).
Exclusion
- Patients who decline consent.
- Patients whose hospital medical records are unavailable for review.
Key Trial Info
Start Date :
October 23 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
275 Patients enrolled
Trial Details
Trial ID
NCT04510688
Start Date
October 23 2019
End Date
June 30 2022
Last Update
October 26 2022
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario Reina Sofía
Córdoba, Andalusia, Spain, 14004
2
Hospital Universitario Juan Ramón Jiménez
Huelva, Andalusia, Spain, 21005
3
Complejo Hospitalario de Jaén
Jaén, Andalusia, Spain, 23007
4
Hospital Son Llatzer
Palma de Mallorca, Balearic Islands, Spain, 07198